Kindred Biosciences

Our goal is to save lives and relieve suffering for the animals in our lives. We bring a determination and dedication to unite our expertise and research creativity in developing humane, effective, and safe therapies for our animal companions that people enjoy today. We are veterinary therapeutics, redefined. As one of the first pet biotech companies in the world, we understood early that to quickly deliver veterinary therapeutics in unmet and under served areas we needed a revolutionary approach. By leveraging the similarities between human and pet diseases, we are creating cutting edge versions of successful human drugs and biologics. Our belief is that this can substantially increase success rate and reduce time to market – increasing the quality of life for the pets with whom we share so much of our lives, providing the veterinary community with innovative treatment options, and, we anticipate, generating solid returns for our investors.
Company Growth (employees)
Type
Public
HQ
Burlingame, US
Founded
2013
Size (employees)
41 (est)
Kindred Biosciences was founded in 2013 and is headquartered in Burlingame, US

Kindred Biosciences Office Locations

Kindred Biosciences has an office in Burlingame
Burlingame, US (HQ)
200 1555 Old Bayshore Hwy

Kindred Biosciences Data and Metrics

Kindred Biosciences Financial Metrics

USD

Net income (Q1, 2017)

(6.5 m)

EBIT (Q1, 2017)

(6.6 m)

Market capitalization (17-Aug-2017)

158 m

Cash (31-Mar-2017)

19.9 m
Kindred Biosciences's current market capitalization is $158 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

3.5 m

General and administrative expense

2.4 m

Operating expense total

5.9 m

EBIT

(5.9 m)

Interest income

101 k

Net Income

(120 k)(27.1 m)(5.8 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

5 m5 m3.4 m3.2 m3.8 m3.8 m

General and administrative expense

1.9 m2.1 m2 m1.9 m2 m2.8 m

Operating expense total

6.9 m7.1 m5.5 m5 m5.8 m6.6 m

EBIT

(6.9 m)(7.1 m)(6.1 m)(5 m)(5.8 m)(6.6 m)

Interest income

29 k33 k52 k79 k93 k131 k

Net Income

(6.9 m)(7.1 m)(6.1 m)(4.9 m)(5.7 m)(6.5 m)
USDFY, 2014FY, 2015FY, 2016

Cash

13 m20 m6.7 m

Inventories

1.9 m1.8 m

Current Assets

101.5 m73.8 m58 m

PP&E

394 k1.2 m2.4 m

Total Assets

101.9 m79.6 m61.6 m

Accounts Payable

420 k717 k410 k

Current Liabilities

2.9 m3.2 m3.9 m

Total Liabilities

3.9 m

Additional Paid-in Capital

130.5 m135 m138.8 m

Retained Earnings

(31.5 m)(58.6 m)(81.1 m)

Total Equity

76.4 m57.7 m

Financial Leverage

1 x1.1 x
USDQ2, 2016Q3, 2016Q1, 2017

Cash

16 m13.3 m19.9 m

Accounts Receivable

2.1 m

Current Assets

62.1 m61.4 m68.4 m

PP&E

1.7 m1.8 m2.6 m

Total Assets

68.9 m65.2 m74 m

Accounts Payable

229 k690 k994 k

Current Liabilities

1.7 m2.6 m2.8 m

Additional Paid-in Capital

136.8 m137.8 m158.8 m

Retained Earnings

(69.6 m)(75.3 m)(87.6 m)

Total Equity

67.2 m62.5 m71.1 m

Financial Leverage

1 x1 x1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(120 k)(27.1 m)(5.8 m)

Depreciation and Amortization

146 k155 k

Inventories

(14.1 m)16 m(37.9 m)

Accounts Payable

6 k30 k(710 k)

Cash From Operating Activities

(62 k)(22.8 m)(18.8 m)

Purchases of PP&E

(729 k)(952 k)

Cash From Investing Activities

29.4 m5.3 m

Cash From Financing Activities

1 m343 k162 k
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(6.9 m)(7.1 m)(6.1 m)(4.9 m)(5.7 m)(6.5 m)

Accounts Receivable

2.1 m

Accounts Payable

347 k1.1 m285 k567 k229 k690 k994 k
Y, 2017

Financial Leverage

1 x

Kindred Biosciences Market Value History

Traffic Overview of Kindred Biosciences

Kindred Biosciences Online and Social Media Presence

Kindred Biosciences Company Life and Culture

You may also be interested in